Effects of Parmigiano Reggiano on Skeletal Muscle Damage in Older Adults

Overview

Aging is associated with the loss of muscle mass and function (sarcopenia) and reduced tissue regenerative capacity. Eccentric exercise (ECC) is a model of RET that can be used with the elderly, due to the ability of the muscle to combine high muscle strength production with low energy cost. ECC contractions are significantly more damaging to the muscles and produce greater muscle strength, for these reasons there is a greater risk of inducing muscle damage before the muscle is able to adapt. Parmigiano Reggiano (PR) has some peculiar bromatological characteristics. The proteins contained in it, and in particular the potentially bioactive peptide sequences, can rapidly provide the amino acids necessary to promote muscle growth and repair during exercise. Furthermore, PR can be an important source of fatty acids, of which a significant amount of short-chain fatty acids (SCFA) which are known to have important clinical effects on body composition and metabolic health and can have a systemic anti-inflammatory effect. Therefore, the central hypothes is that PR consumed during RET can provide more energy substrates and improve muscle recovery. To date, no studies have studied its function on recovery from exercise nor in the elderly.

Full Title of Study: “Effects of Parmigiano Reggiano on Exercise Induced Muscle Damage in Older Adults”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: October 31, 2021

Interventions

  • Dietary Supplement: Parmigiano Reggiano
    • subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
  • Dietary Supplement: Whey Protein
    • subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session

Arms, Groups and Cohorts

  • Experimental: Young adults
    • participants will perform an eccentric exercise bout after 10 days of dietary supplementation
  • Active Comparator: Older adults
    • participants will perform an eccentric exercise bout after 10 days of dietary supplementation

Clinical Trial Outcome Measures

Primary Measures

  • maximum volountary contraction (MVC)
    • Time Frame: Change from baseline to up to 5 days
    • maximal muscle volountary contraction mesured in Newton

Secondary Measures

  • reactive Proteinc C
    • Time Frame: Change from baseline to up to 5 days
    • plasmatic levels of reactive Proteinc C (mg/dL) as a markers of muscle damage
  • Creatin Kinase
    • Time Frame: Change from baseline to up to 5 days
    • plasmatic levels of Creatin Kinase (mmol/dL) as a markers of muscle damage
  • IL-6
    • Time Frame: Change from baseline to up to 5 days
    • plasmatic levels of IL-6 (mg/dL) as a markers of muscle damage
  • delayed onset muscle soreness (DOMS)
    • Time Frame: Change from baseline to up to 5 days
    • level of delayed onset muscle soreness (DOMS) masured via Visual Analogue Scale (VAS) scale where 0 is the minimal value (no pain) and 10 is the maximum value (maximum pain).

Participating in This Clinical Trial

Inclusion Criteria

  • age >60 years old or >18 and < 30 years old – BMI >18 and <30 kg/m2 – stable body weight in the past 3 months – valid medical certifacate for practice of physical activity Exclusion Criteria:

  • diabetes or pre-diabetes as for ADA guidelines – chronic diseases (cardiovascular, liver, respiratory, cancer, etc) – acute inflammatory status – regular practice of intense physical activity (>2 sessions/week) – treatment with steroids in the past 3 months – regular use of >50g/die of Parmigiano Reggiano

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Padova
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Tatiana Moro, PhD, 0498275306, tatiana.moro@unipd.it

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.